nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.01.2005 | Original Paper

A single nucleotide polymorphism in the MMP-9 promoter affects tumor progression and invasive phenotype of gastric cancer

verfasst von: Shunji Matsumura, Naohide Oue, Hirofumi Nakayama, Yasuhiko Kitadai, Kazuhiro Yoshida, Yoshiyuki Yamaguchi, Kazue Imai, Kei Nakachi, Keisuke Matsusaki, Kazuaki Chayama, Wataru Yasui

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 1/2005

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Matrix metalloproteinase-9 (MMP-9, gelatinase B) plays a key role in cancer invasion and metastasis by degradating the extracellular matrix (ECM) and basement membrane barriers. A cytosine (C)-thymidine (T) single nucleotide polymorphism (SNP) at position –1562 in the MMP-9 promoter is reported to affect expression of this gene. The purpose of this study was to investigate the relation between the –1562 C/T polymorphism and the development and progression of gastric cancer.

Methods

The study population included 177 gastric cancer patients and 224 healthy control subjects. The SNP in the MMP-9 promoter was analyzed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and sequencing. Genotype frequencies were compared between patients and controls, and the association of genotypes with clinicopathological features was studied.

Results

Genotype frequencies in gastric cancer patients were similar to those in control subjects (P = 0.223). However, significant association was found between degree of tumor invasion, clinical stage, and lymphatic invasion and the MMP-9 polymorphism in gastric cancer patients (P<0.05, for each).

Conclusions

Our results indicate that the T allele in the MMP-9 promoter is associated with the invasive phenotype of gastric cancer.

Baker EA, Leaper DJ (2003) The plasminogen activator and matrix metalloproteinase systems in colorectal cancer: relationship to tumour pathology. Eur J Cancer 39:981–988CrossRefPubMed

Behrens P, Rothe M, Wellmann A, Krischler J, Wernert N (2001) The Ets-1 transcription factor is up-regulated together with MMP-1 and MMP-9 in the stroma of pre-invasive breast cancer. J Pathol 194:43–50CrossRefPubMed

Chicoine E, Esteve PO, Robledo O, Van Themsche C, Potworowski EF, St-Pierre Y (2002) Evidence for the role of promoter methylation in the regulation of MMP-9 gene expression. Biochem Biophys Res Commun 297:765–772CrossRefPubMed

Ferrand PE, Parry S, Sammel M, Macones GA, Kuivaniemi H, Romero R, Strauss JF 3rd (2002) A polymorphism in the matrix metalloproteinase-9 promoter is associated with increased risk of preterm premature rupture of membranes in African Americans. Mol Hum Reprod 8:494–501CrossRefPubMed

Forget MA, Desrosiers RR, Beliveau R (1999) Physiological roles of matrix metalloproteinases; implications for tumor growth and metastasis. Can J Physiol Pharmacol 77:465–480CrossRefPubMed

Gum R, Lengyel E, Juarez J, Chen JH, Sato H, Seiki M, Boyd D (1996) Stimulation of 92-kDa gelatinase B promoter activity by ras is mitogen-activated protein kinase kinase 1-independent and requires multiple transcription factor binding sites including closely spaced PEA3/ets and AP-1 sequences. J Biol Chem 271:10672–10680CrossRefPubMed

Hujanen ES, Vaisanen A, Zheng A, Tryggvason K, Turpeenniemi-Hujanen T (1994) Modulation of M(r) 72,000 and M(r) 92,000 type-IV collagenase (gelatinase A and B) gene expression by interferons alpha and gamma in human melanoma. Int J Cancer 58:582–586PubMed

Japanese Gastric Cancer Association (1998) Japanese classification of gastric carcinoma. 2nd English Edition. Gastric Cancer 1:10–24CrossRefPubMed

Jones JL, Glynn P, Walker RA (1999) Expression of MMP-2 and MMP-9, their inhibitors, and the activator MT1-MMP in primary breast carcinomas. J Pathol 189:161–168CrossRefPubMed

Kallakury BV, Karikehalli S, Haholu A, Sheehan CE, Azumi N, Ross JS (2001) Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin Cancer Res 7:3113–3119PubMed

Kohn EC, Liotta LA (1995) Molecular insights into cancer invasion: strategies for prevention and intervention. Cancer Res 55:1856–1862PubMed

Kuraoka K, Matsumura S, Hamai Y, Nakachi K, Imai K, Matsusaki K, Oue N, Ito R, Nakayama H, Yasui W (2003) A single nucleotide polymorphism in the transmenbrane domain coding region of HER-2 is associated with development and malignant phenotype of gastric cancer. Int J Cancer 107:593–596CrossRefPubMed

Lauren P (1965) The two histological main types of gastric carcinoma. Diffuse and so-called intestinal type carcinoma: an attempt at histological classification. Acta Pathol Microbiol Scand 64:31–49PubMed

Liotta LA, Steeg PS, Stetler-Stevenson WG (1991) Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64:327–336CrossRefPubMed

Matsumura S, Oue N, Kitadai Y, Chayama K, Yoshida K, Yamaguchi Y, Toge T, Imai K, Nakachi K, Yasui W (2004) A single nucleotide polymorphism in the MMP-1 promoter is correlated with histological differentiation of gastric cancer. J Cancer Res Clin Oncol 130:259–265CrossRef

McDonnell S, Matrisian LM (1990) Stromelysin in tumor progression and metastasis. Cancer Metastasis Rev 9:305–319PubMed

Murray GI, Duncan ME, Arbuckle E, Melvin WT, Fothergill JE (1998) Matrix metalloproteinases and their inhibitors in gastric cancer. Gut 43:791–797PubMed

Nakayama T, Ito M, Ohtsuru A, Naito S, Nakashima M, Fagin JA, Yamashita S, Sekine I (1996) Expression of the Ets-1 proto-oncogene in human gastric carcinoma: correlation with tumor invasion. Am J Pathol 149:1931–1939PubMed

Nagase H, Woessner JF Jr (1999) Matrix metalloproteinases. J Biol Chem 274:21491–494CrossRefPubMed

Oue N, Motoshita J, Yokozaki H, Hayashi K, Tahara E, Taniyama K, Matsusaki K, Yasui W (2002) Distinct promoter hypermethylation of p16INK4a, CDH1, and RAR-ß in intestinal, diffuse-adherent, and diffuse-scattered type gastric carcinomas. J Pathol 198:55–59CrossRefPubMed

Oue N, Oshimo Y, Nakayama H, Ito R, Yoshida K, Matsusaki K, Yasui W (2003) DNA methylation of multiple genes in gastric carcinoma: association with histological type and CpG island methylator phenotype. Cancer Sci 94:901–905PubMed

Ozalp S, Tanir HM, Yalcin OT, Kabukcuoglu S, Oner U, Uray M (2003) Prognostic value of matrix metalloproteinase-9 (gelatinase-B) expression in epithelial ovarian tumors. Eur J Gynaecol Oncol 24:417–420PubMed

Park CC, Bissell MJ, Barcellos-Hoff MH (2000) The influence of the microenvironment on the malignant phenotype. Mol Med Today 6:324–329CrossRefPubMed

Rao JS, Steck PA, Mohanam S, Stetler-Stevenson WG, Liotta LA, Sawaya R (1993) Elevated levels of M(r) 92,000 type IV collagenase in human brain tumors. Cancer Res 53:2208–2211PubMed

Sakata K, Satoh M, Someya M, Asanuma H, Nagakura H, Oouchi A, Nakata K, Kogawa K, Koito K, Hareyama M, Himi T (2004) Expression of matrix metalloproteinase 9 is a prognostic factor in patients with non-Hodgkin lymphoma. Cancer 100:356–365CrossRefPubMed

Sehgal I, Baley PA, Thompson TC (1996) Transforming growth factor beta1 stimulates contrasting responses in metastatic versus primary mouse prostate cancer-derived cell lines in vitro. Cancer Res 56:3359–3365PubMed

Sobin LH, Wittekind CH (eds) (2002) TNM classification of malignant tumors, 6th edn. Wiley-Liss, New York, pp 65–68

Tanioka Y, Yoshida T, Yagawa T, Saiki Y, Takeo S, Harada T, Okazawa T, Yanai H, Okita K (2003) Matrix metalloproteinase-7 and matrix metalloproteinase-9 are associated with unfavourable prognosis in superficial oesophageal cancer. Br J Cancer 89:2116–2121CrossRefPubMed

Wroblewski LE, Pritchard DM, Carter S, Varro A (2002) Gastrin-stimulated gastric epithelial cell invasion: the role and mechanism of increased matrix metalloproteinase 9 expression. Biochem J 365:873–879PubMed

Yasui W, Yokozaki H, Fujimoto J, Naka K, Kuniyasu H, Tahara E (2000) Genetic and epigenetic alterations in multistep carcinogenesis of the stomach. J Gastroenterol 35:111–115PubMed

Zhang B, Ye S, Hermann SM, Eriksson P, de Maat M, Evans A, Arveiler D, Luc G, Cambien F, Hamsten A, Watkins H, Henney AM (1999) Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation 99:1788–794PubMed

Zhang S, Li L, Lin JY, Lin H (2003) Imbalance between expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in invasiveness and metastasis of human gastric carcinoma. World J Gastroenterol 9:899–904PubMed

Titel: A single nucleotide polymorphism in the MMP-9 promoter affects tumor progression and invasive phenotype of gastric cancer
verfasst von: Shunji Matsumura
Naohide Oue
Hirofumi Nakayama
Yasuhiko Kitadai
Kazuhiro Yoshida
Yoshiyuki Yamaguchi
Kazue Imai
Kei Nakachi
Keisuke Matsusaki
Kazuaki Chayama
Wataru Yasui
Publikationsdatum: 01.01.2005
Verlag: Springer-Verlag
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 1/2005
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-004-0621-4

Neu im Fachgebiet Onkologie

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

A single nucleotide polymorphism in the MMP-9 promoter affects tumor progression and invasive phenotype of gastric cancer

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2005

Allogeneic hematopoietic cell transplantation: from experimental biology to clinical care

A rationale for neoadjuvant systemic treatment followed by surgical assessment and intraperitoneal chemotherapy in patients presenting with non-surgically resectable ovarian or primary peritoneal cancers

Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme

The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain

Expression of e-cadherin in high-risk breast cancer

Listeria monocytogenes produces a pro-invasive factor that signals via ErbB2/ErbB3 heterodimers

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie